Cost Effectiveness Of Linezolid In Central America
Status:
Withdrawn
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The therapy with Linezolid (LIN) represents better cost-effectiveness vs. Vancomycin (VAN)
for the treatment of nosocomial Pneumonia associate to ventilator (VAP).